Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.21
ACRX's Cash to Debt is ranked lower than
51% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ACRX: 2.21 )
Ranked among companies with meaningful Cash to Debt only.
ACRX' s 10-Year Cash to Debt Range
Min: 0.31  Med: 3.44 Max: N/A
Current: 2.21
Equity to Asset 0.53
ACRX's Equity to Asset is ranked lower than
64% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ACRX: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
ACRX' s 10-Year Equity to Asset Range
Min: -0.01  Med: 0.54 Max: 0.69
Current: 0.53
-0.01
0.69
F-Score: 2
Z-Score: -1.24
M-Score: -3.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -508.26
ACRX's Operating margin (%) is ranked lower than
88% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. ACRX: -508.26 )
Ranked among companies with meaningful Operating margin (%) only.
ACRX' s 10-Year Operating margin (%) Range
Min: -1805.22  Med: -981.40 Max: -22.6
Current: -508.26
-1805.22
-22.6
Net-margin (%) -448.14
ACRX's Net-margin (%) is ranked lower than
88% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ACRX: -448.14 )
Ranked among companies with meaningful Net-margin (%) only.
ACRX' s 10-Year Net-margin (%) Range
Min: -1875.09  Med: -1016.46 Max: -79.4
Current: -448.14
-1875.09
-79.4
ROE (%) -68.01
ACRX's ROE (%) is ranked lower than
84% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ACRX: -68.01 )
Ranked among companies with meaningful ROE (%) only.
ACRX' s 10-Year ROE (%) Range
Min: -130.03  Med: -55.67 Max: -43.78
Current: -68.01
-130.03
-43.78
ROA (%) -37.96
ACRX's ROA (%) is ranked lower than
73% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. ACRX: -37.96 )
Ranked among companies with meaningful ROA (%) only.
ACRX' s 10-Year ROA (%) Range
Min: -134.55  Med: -73.84 Max: -26.84
Current: -37.96
-134.55
-26.84
ROC (Joel Greenblatt) (%) -315.87
ACRX's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. ACRX: -315.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2973.59  Med: -907.22 Max: -173.98
Current: -315.87
-2973.59
-173.98
Revenue Growth (3Y)(%) 26.00
ACRX's Revenue Growth (3Y)(%) is ranked higher than
94% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ACRX: 26.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 26
Current: 26
0
26
EBITDA Growth (3Y)(%) -12.50
ACRX's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ACRX: -12.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -72.35 Max: -12.5
Current: -12.5
EPS Growth (3Y)(%) -12.80
ACRX's EPS Growth (3Y)(%) is ranked lower than
66% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ACRX: -12.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -67.45 Max: -12.8
Current: -12.8
» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ACRX Guru Trades in Q3 2014

Paul Tudor Jones 11,400 sh (New)
Louis Moore Bacon Sold Out
» More
Q4 2014

ACRX Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
Q1 2015

ACRX Guru Trades in Q1 2015

Paul Tudor Jones 52,600 sh (New)
» More
Q2 2015

ACRX Guru Trades in Q2 2015

Paul Tudor Jones 24,100 sh (-54.18%)
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.97
ACRX's P/B is ranked lower than
77% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. ACRX: 5.97 )
Ranked among companies with meaningful P/B only.
ACRX' s 10-Year P/B Range
Min: 2.16  Med: 6.19 Max: 78
Current: 5.97
2.16
78
P/S 27.94
ACRX's P/S is ranked lower than
91% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ACRX: 27.94 )
Ranked among companies with meaningful P/S only.
ACRX' s 10-Year P/S Range
Min: 7.21  Med: 42.50 Max: 163
Current: 27.94
7.21
163
Current Ratio 4.02
ACRX's Current Ratio is ranked higher than
68% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ACRX: 4.02 )
Ranked among companies with meaningful Current Ratio only.
ACRX' s 10-Year Current Ratio Range
Min: 0.43  Med: 4.31 Max: 20.39
Current: 4.02
0.43
20.39
Quick Ratio 4.02
ACRX's Quick Ratio is ranked higher than
77% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ACRX: 4.02 )
Ranked among companies with meaningful Quick Ratio only.
ACRX' s 10-Year Quick Ratio Range
Min: 0.43  Med: 4.31 Max: 20.39
Current: 4.02
0.43
20.39

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.53
ACRX's Price/Net Cash is ranked higher than
60% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 13.32 vs. ACRX: 9.53 )
Ranked among companies with meaningful Price/Net Cash only.
ACRX' s 10-Year Price/Net Cash Range
Min: 2.2  Med: 7.81 Max: 25
Current: 9.53
2.2
25
Price/Net Current Asset Value 8.45
ACRX's Price/Net Current Asset Value is ranked lower than
57% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. ACRX: 8.45 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.14  Med: 8.00 Max: 927
Current: 8.45
2.14
927
Price/Tangible Book 5.97
ACRX's Price/Tangible Book is ranked lower than
61% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. ACRX: 5.97 )
Ranked among companies with meaningful Price/Tangible Book only.
ACRX' s 10-Year Price/Tangible Book Range
Min: 2.08  Med: 6.23 Max: 57.94
Current: 5.97
2.08
57.94
Price/Median PS Value 0.66
ACRX's Price/Median PS Value is ranked higher than
81% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ACRX: 0.66 )
Ranked among companies with meaningful Price/Median PS Value only.
ACRX' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 0.93 Max: 3.78
Current: 0.66
0.17
3.78
Earnings Yield (Greenblatt) (%) -16.88
ACRX's Earnings Yield (Greenblatt) (%) is ranked lower than
81% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. ACRX: -16.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -46.1  Med: 0.00 Max: 0
Current: -16.88
-46.1
0

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 20 7 18 45
EPS($) -0.52 -0.71 -0.34 -0.06
EPS without NRI($) -0.52 -0.71 -0.34 -0.06

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceutica Oct 15 2014 
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
3 Catalysts To Watch Over The Next Couple Months For This Pharma Co. Sep 02 2015
Coverage initiated on AcelRx by H.C. Wainwright Sep 02 2015
AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September Aug 26 2015
AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September Aug 26 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Aug 21 2015
Why AceIRx (ACRX) Could Be a Potential Winner Aug 21 2015
ACELRX PHARMACEUTICALS INC Financials Aug 11 2015
10-Q for AcelRx Pharmaceuticals, Inc. Aug 06 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 04 2015
Edited Transcript of ACRX earnings conference call or presentation 3-Aug-15 8:30pm GMT Aug 04 2015
ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 04 2015
AcelRx Pharmaceuticals reports 2Q loss Aug 03 2015
AcelRx Pharmaceuticals reports 2Q loss Aug 03 2015
AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015... Aug 03 2015
AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 03 2015
AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015... Aug 03 2015
Q2 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close Aug 03 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 29 2015
AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call... Jul 29 2015
AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call... Jul 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK